Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

P. Conte, A. Frassoldati, G. Bisagni, A.A. Brandes, M. Donadio, O. Garrone, F. Piacentini, L. Cavanna, F. Giotta, M. Aieta, V. Gebbia, A. Molino, A. Musolino, A. Ferro, R. Maltoni, S. Danese, C. Zamagni, A. Rimanti, K. Cagossi, A. RussoP. Pronzato, F. Giovanardi, G. Moretti, L. Lombardo, A. Schirone, A. Beano, L. Amaducci, E.A. Bajardi, R. Vicini, S. Balduzzi, R. D'Amico, V. Guarneri, Reader study level-I and level-II Groups

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)2328-2333
Number of pages6
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
Issue number12
DOIs
Publication statusPublished - 2018

Cite this

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. / Conte, P.; Frassoldati, A.; Bisagni, G.; Brandes, A.A.; Donadio, M.; Garrone, O.; Piacentini, F.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Molino, A.; Musolino, A.; Ferro, A.; Maltoni, R.; Danese, S.; Zamagni, C.; Rimanti, A.; Cagossi, K.; Russo, A.; Pronzato, P.; Giovanardi, F.; Moretti, G.; Lombardo, L.; Schirone, A.; Beano, A.; Amaducci, L.; Bajardi, E.A.; Vicini, R.; Balduzzi, S.; D'Amico, R.; Guarneri, V.; Groups, Reader study level-I and level-II.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, No. 12, 2018, p. 2328-2333.

Research output: Contribution to journalArticle

Conte, P, Frassoldati, A, Bisagni, G, Brandes, AA, Donadio, M, Garrone, O, Piacentini, F, Cavanna, L, Giotta, F, Aieta, M, Gebbia, V, Molino, A, Musolino, A, Ferro, A, Maltoni, R, Danese, S, Zamagni, C, Rimanti, A, Cagossi, K, Russo, A, Pronzato, P, Giovanardi, F, Moretti, G, Lombardo, L, Schirone, A, Beano, A, Amaducci, L, Bajardi, EA, Vicini, R, Balduzzi, S, D'Amico, R, Guarneri, V & Groups, RSL-IAL-II 2018, 'Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, no. 12, pp. 2328-2333. https://doi.org/10.1093/annonc/mdy414
Conte, P. ; Frassoldati, A. ; Bisagni, G. ; Brandes, A.A. ; Donadio, M. ; Garrone, O. ; Piacentini, F. ; Cavanna, L. ; Giotta, F. ; Aieta, M. ; Gebbia, V. ; Molino, A. ; Musolino, A. ; Ferro, A. ; Maltoni, R. ; Danese, S. ; Zamagni, C. ; Rimanti, A. ; Cagossi, K. ; Russo, A. ; Pronzato, P. ; Giovanardi, F. ; Moretti, G. ; Lombardo, L. ; Schirone, A. ; Beano, A. ; Amaducci, L. ; Bajardi, E.A. ; Vicini, R. ; Balduzzi, S. ; D'Amico, R. ; Guarneri, V. ; Groups, Reader study level-I and level-II. / Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29, No. 12. pp. 2328-2333.
@article{6e7d13c70767453ca8788249aec2a9f7,
title = "Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡",
author = "P. Conte and A. Frassoldati and G. Bisagni and A.A. Brandes and M. Donadio and O. Garrone and F. Piacentini and L. Cavanna and F. Giotta and M. Aieta and V. Gebbia and A. Molino and A. Musolino and A. Ferro and R. Maltoni and S. Danese and C. Zamagni and A. Rimanti and K. Cagossi and A. Russo and P. Pronzato and F. Giovanardi and G. Moretti and L. Lombardo and A. Schirone and A. Beano and L. Amaducci and E.A. Bajardi and R. Vicini and S. Balduzzi and R. D'Amico and V. Guarneri and Groups, {Reader study level-I and level-II}",
note = "Export Date: 7 January 2019",
year = "2018",
doi = "10.1093/annonc/mdy414",
language = "English",
volume = "29",
pages = "2328--2333",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "12",

}

TY - JOUR

T1 - Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

AU - Conte, P.

AU - Frassoldati, A.

AU - Bisagni, G.

AU - Brandes, A.A.

AU - Donadio, M.

AU - Garrone, O.

AU - Piacentini, F.

AU - Cavanna, L.

AU - Giotta, F.

AU - Aieta, M.

AU - Gebbia, V.

AU - Molino, A.

AU - Musolino, A.

AU - Ferro, A.

AU - Maltoni, R.

AU - Danese, S.

AU - Zamagni, C.

AU - Rimanti, A.

AU - Cagossi, K.

AU - Russo, A.

AU - Pronzato, P.

AU - Giovanardi, F.

AU - Moretti, G.

AU - Lombardo, L.

AU - Schirone, A.

AU - Beano, A.

AU - Amaducci, L.

AU - Bajardi, E.A.

AU - Vicini, R.

AU - Balduzzi, S.

AU - D'Amico, R.

AU - Guarneri, V.

AU - Groups, Reader study level-I and level-II

N1 - Export Date: 7 January 2019

PY - 2018

Y1 - 2018

U2 - 10.1093/annonc/mdy414

DO - 10.1093/annonc/mdy414

M3 - Article

VL - 29

SP - 2328

EP - 2333

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

ER -